Nov 3, 2021
WHO has announced that it has granted emergency use listing for Covaxin developed by Bharat Biotech. This adds another vaccine to the approved list by WHO to prevent COVID19.
Also read: Top 10 pharma companies by revenues in 2021
The UN body announced that the Technical Advisory Group reviewed the vaccine, and the vaccine meets the WHO's standards to prevent COVID19. Further, the vaccine benefits outweigh the risks.
The vaccine was also reviewed by the Strategic Advisory Group of Experts on Immunization (SAGE), which recommended the vaccine for adults of all age groups with a time difference of four weeks between the two doses.
Also read: FDA approved Novartis Scembli for chronic myeloid leukemia
After the administration of the second dose, COVAXIN demonstrated an efficacy of 78%. The agency further acclaimed the easy storage requirements and its suitability for the lower and middle-income countries.
The agency further mentioned that the listing is a vital tool to prevent COVID19.